b007
mAbexperimental
Clinical trial activity
4 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
0
Phase 3
3
Phase 4
0
Earliest trial started Feb 28, 2023 (NCT05668403)
Timeline
Indications
Mechanism of action
- B-lymphocyte antigen CD20BINDING AGENT
CD20
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06470191 | Phase 2/Phase 3 (Phase 3) | Jul 30, 2024 | Shanghai Pharmaceuticals Holding Co., Ltd |
| NCT06454357 | Phase 2/Phase 3 (Phase 3) | Jul 12, 2024 | Shanghai Pharmaceuticals Holding Co., Ltd |
| NCT06447597 | Phase 2/Phase 3 (Phase 3) | Jul 1, 2024 | Shanghai Pharmaceuticals Holding Co., Ltd |
| NCT05668403 | Phase 1 | Feb 28, 2023 | Shanghai Pharmaceuticals Holding Co., Ltd |
Showing 4 of 4 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Shanghai Pharmaceuticals Holding Co., Ltd | For profit | 4 | 4 | 2 | 2023 |
1 organizations
Page 1 / 1